Table 3:
Bispecific antibodies under investigation in FL.
| Bispecific Antibody | Mosunetuzumab | Mosunetuzumab + Lenalidomide | Epcoritamab | Glofitamab | Odronextamab |
|---|---|---|---|---|---|
| Phase | 1/2 | 1 | 1/2 | 1/2 | 1 |
| Trial | NCT02500407 | NCT04246086 | NCT03625037 | NCT03075696 | NCT02290951 |
| Patients (FL) | 90 (90) | 29 (29) | 68 (12) | 53 (mono) 19 (+obin) |
127 (28) |
| Median prior therapies | 3 (2-10) | 1 (1-6) | 5 (3-8) | 3 (1-12) (mono) 2 (1-5) (+obin) |
3 (1-11) |
| ORR (CR) | 80% (60%) | 90% (66%) | 90% (50%) | 81% (70%) (mono) 100% (74%) (+obin) |
93% (75%) |
| Median DOR | 22.8 months | NR | NR | NR | 8.1 months |
| Median PFS | 17.9 months | NR | NR | NR | 12.8 months |
| CRS (grade ≥ 3) | 2% | 0% | 0% | 4% (mono) 0% (+obin) |
6% |
| Neurotoxicity (grade ≥ 3) | 0% | 0% | 3% | 0% (mono) 0% (+obin) |
4% |
| Median follow-up | 18.3 months | 5.4 months | 13.6 months | 4.4 months (mono) 5.5 months (+obin) |
3.9 months |
FL = follicular lymphoma, CR = complete response, CRS = cytokine release syndrome, mono = monotherapy, NR = not reported, obin = obinutuzumab, ORR = overall response rate, PFS = progression free survival, RP2D = recommended phase 2 dose.